Jean-Baptiste Alberge
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Bridge grant
Open Date: 2021-01-01
Close Date: 2021-01-01
Grant: Close
Postdoctoral fellowship
Open Date: 2021-01-01
Close Date: 2022-01-01
Grant: Close
Mapping the hydroxymethylome in Multiple Myeloma
Open Date: 2017-01-01
Close Date: 2020-01-01
Articles (23)
Year:
2026
Year:
2026
The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for patients with MM with 1q+ stands to benefit a large portion of patients in need of more effective management. Here, we used large-scale dependency screens and drug screens to systematically characterize the therapeutic vulnerabilities of MM with 1q+ and displayed increased sensitivity to myeloid cell leukemia-1 (MCL1) and phosphatidyl inositol 3-kinase (PI3K) inhibitors. Using single-cell RNA sequencing, we compared subclones with and without 1q+ within the same patient tumors and demonstrated that 1q+ is associated with higher levels of MCL1 and the PI3K pathway. Furthermore, by isolating isogenic clones with different copy number profiles for part of the chromosome 1q arm, we observed increased sensitivity to MCL1 and PI3K inhibitors with arm-level gain. Lastly, we demonstrated synergy between MCL1 and PI3K inhibitors and dissected their mechanism of action in MM with 1q+, uncovering a cytostatic effect. In conclusion, this study highlights that MM with 1q+ may present enhanced sensitivity to MCL1 and PI3K inhibitors, enabling their use at lower doses without sacrificing efficacy, and may thus accelerate the development of targeted therapy for patients with MM and 1q+.
Year:
2025
Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC (FLC) κ, λ, and their ratio (κ/λ) reference ranges based on a mostly White population. We investigated FLC values in a racially diverse population by screening 10 035 individuals for heavy chain MG, identifying 9028 negative cases whose FLC were measured. Participants included 4149 from the PROMISE study (United States, n = 2383; South Africa, n = 1766) and 4879 from the Mass General Brigham Biobank, with 44% self-identifying as Black. Using standard FLC reference ranges, 1074 of 10 035 individuals (10.7%) were diagnosed with LC monoclonal gammopathy of undetermined significance (MGUS), with 99% being κ-restricted. In the United States, 14.8% of Black and 4% of White individuals were diagnosed (P < .01). Among US participants of African (AFR) and European (EUR) genetic ancestry, 14.4% AFR and 2.9% EUR were diagnosed (P < .01). Among South Africans (100% Black), 27.8% were diagnosed using standard ranges. To avoid overdiagnosis, we propose a new κ/λ ratio reference range (0.686 to 2.10) for populations of AFR descent with normal renal function, with standard values for κ and λ being 7.97 to 77.50 mg/L and 6.20 to 49.20 mg/L, respectively. This reduces LC-MGUS overdiagnosis by 91% (10.7% vs 0.97%). Using the new reference, LC-MGUS accounts for 8.8% of MGUS cases, with 74% being κ-restricted, consistent with LC myeloma rates. These findings highlight the importance of basing disease definitions, such as MGUS, on diverse populations. Adopting our proposed FLC reference values would reduce MGUS overdiagnosis among Black individuals, avoiding unnecessary financial, psychological, and medical consequences. This study includes data from NCT03689595.
Year:
2025
Year:
2025
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.7–NR, median follow-up 50 months). The secondary endpoint, biochemical PFS, was 48.6 months (95% CI: 39.9–NR) and coincided with or preceded SLiM-CRAB in eight patients. For additional secondary objectives, the overall response rate was 93% with 31% achieving complete response (CR) and 45% very good partial response (VGPR) or better. CR correlated strongly with the absence of SLiM-CRAB and biochemical progression. MRD-negativity (10 -5 sensitivity) predicted a 5-year biochemical PFS of 100% versus 40% in MRD-positive patients (p = 0.051), demonstrating that deep responses significantly improve time to progression. Exploratory single-cell RNA sequencing linked tumor MHC class I expression to proteasome inhibitor response, and a lower proportion of GZMB+ T cells within clonally expanded CD8+ T cells associated with suboptimal outcomes.
Year:
2025
Year:
2025
Aberrant alterations in genome copy number, chromatin accessibility, and transcriptional programs all play pivotal roles in cancer. The Numbat algorithm has been widely adopted to perform copy number variation (CNV) inference from single-cell RNA sequencing (scRNA-seq) data. Here, we introduce Numbat-multiome that extends the capabilities of Numbat to perform CNV inference from both scRNA-seq and accessible chromatin profiles (through single-cell Assay of Transposase [Tn5]-Accessible Chromatin sequencing [scATAC-seq] data), either separately or in an integrated manner. Our approach unifies data originating from different modalities through a binning strategy that relies on a common genomic coordinate system across modalities. We demonstrate the tool’s robust performance in four running modes (RNA gene, RNA bin, ATAC bin, and Combined bin) using benchmark cohorts of tumors with dynamic changes in expression patterns and copy number heterogeneity, including early-stage multiple myeloma and Richter’s syndrome arising from chronic lymphocytic leukemia, validated against whole-genome sequencing. Numbat-multiome achieves high precision and recall (median F1>0.9) across different CNV event types, with consistent performance across sample types and event lengths. The tool’s ability to track clonal evolution in serial samples and identify rare subclones allows for integration of epigenomic profiles at the subclonal level, providing new insights into the stepwise genetic and epigenetic changes underlying cancer phenotypic shifts.
Year:
2025
Year:
2025
Supplementary data contains additional Materials and Methods used to generate results presented only in the supplementary figures and tables, as well as more detailed bioinformatics methods. Figure S1 shows correlation between clinical measures of disease pathology, survival, and circulating tumor cells enumeration. Figure S2 shows characteristics of isolated circulating tumor cells from peripheral blood of precursor disease patients. Figure S3 shows cohort-level genomic characterization of tumor in MM precursor stages with CTCs. Figure S4 shows longitudinal and tissue-matched genomic characterization of driver mutations. Figure S5 shows comparison of mutational processes between BMPCs and CTCs assigned to most likely PCAWG composite reference signature. Table S1 shows clinical characteristics and sampling of participants in this study. Table S2 shows whole-genome sequencing coverage and library metrics. Table S3 shows clinical BM FISH results and cells recovered for cohort with matched samples. Table S4 shows comparison of BCR sequence between BMPCs and CTCs. Table S5 shows clinical BM FISH results of peripheral blood only cohort and CTCs recovered. Table S6 shows enumeration of single nucleotide variants and short insertions and deletions discovered from WGS of CTCs. Table S7 shows enumeration of structural variants reconstructed from WGS of CTCs.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (32)
Stéphane Minvielle
CNRS Délégation Bretagne et Pays de Loire
Meletios Dimopoulos
Professor
National and Kapodistrian University of Athens
Shaji Kumar
Medical College of Wisconsin
Kwee Yong
University College London
Mansour Poorebrahim
Deutsches Krebsforschungszentrum
Paola Neri
University of Calgary
Kirsten Kübler
University Hospital Bonn
Hermann Einsele
University Hospital Würzburg
Brian Walker
Professor
University of Miami
María-Victoria Mateos
University Hospital of Salamanca
Russell J.H. Ryan
Associate Professor
University of Michigan Medical School
Annie Cowan
Dana-Farber Cancer Institute
Luca Pinello
Associate Member
Broad Institute
Kendell Clement
Assistant Professor
University of Utah
Bachisio Ziccheddu
Sylvester Comprehensive Cancer Center, University of Miami
K. Martin Kortüm
University Hospital Würzburg
Irene Ghobrial
Professor of Medicine
Dana-Farber Cancer Institute
Catherine Pellat-Deceunynck
Université de Nantes
Niccolò Bolli
Associate Professor
University of Milan
Esther Rheinbay
Massachusetts General Hospital
Jesus F. San Miguel
-
Gad Getz
Broad Institute
Wenlong Chen
Senior Researcher
University of Witwatersrand
Jesse Engreitz
Stanford University
Mathieu Lupien
Senior Scientist
University Health Network
Tim Coorens
Research Group Leader
European Bioinformatics Institute
Sebastian Theurich
Oberarzt, Hämatologie und Onkologie, W2 Professor für Krebs- und Immunmetabolismus
Klinikum der Universität München
Bruno David Lourenço Paiva
Clinica Universidad de Navarra
Stephen Chong
National University of Singapore (NUS)
Yoshinobu Konishi
Assistant Professor
Kyoto University Hospital
Marc S. Raab
University Hospital Heidelberg
Michelle Aranha
Computational Scientist
Broad Institute
Make your next move.
Prepare your application
Review drafts before you send them.